Invention Grant
- Patent Title: Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
-
Application No.: US14774645Application Date: 2014-03-13
-
Publication No.: US09758495B2Publication Date: 2017-09-12
- Inventor: Ana Gonzalez Buenrostro , Yihong Li , Julio C. Medina , Steven H. Olson
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: Amgen Inc.
- Current Assignee: Amgen Inc.
- Current Assignee Address: US CA Thousand Oaks
- Agent Markus Bergauer
- International Application: PCT/US2014/026584 WO 20140313
- International Announcement: WO2014/151863 WO 20140925
- Main IPC: C07D265/32
- IPC: C07D265/32 ; C07D413/06 ; C07D417/06
Abstract:
The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).
Public/Granted literature
- US20160039774A1 HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2016-02-11
Information query
